August 15, 2022 11:25 AM EDT
News Briefing

An an­tibi­otics play­er ax­es staff in wake of PhI­II fail; Hori­zon to fund an­ti­body de­vel­op­ment, with op­tion to buy

John Carroll

Editor & Founder

Kyle LaHucik

Senior Reporter

A few weeks af­ter wav­ing a white flag of sur­ren­der on their late-stage study of a new an­tibi­ot­ic, Con­tra­Fect CEO Roger Pomer­antz has now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bi­par­ti­san 'pill penal­ty' fix and oth­er bills vie for in­clu­sion in rec­on­cil­i­a­tion pack­age

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times